Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 6, 2010, Pages 669-675

  Leenen, Frans H H ^a   Coletta, Elizabeth ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Age; Amlodipine; Antihypertensive response; Dihydropyridine; Duration of action; Felodipine; Pharmacokinetics; Plasma levels

Indexed keywords

AMLODIPINE; FELODIPINE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; FELODIPINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 78751646435     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181fc45bb     Document Type: Article

References (20)

1. Abernethy DR, Gutkowska J, Winterbottom LM. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther. 1990; 48:76-86.
2. Blychert E, Edgar B, Elmfeldt D, Hedner. Plasma concentration-effect relationships for felodipine: a meta analysis. Clin Pharmacol Ther. 1992; 52:80-89.
3. Donnelly R, Meredith PA, Miller SHK, et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther. 1993;54:303-310.
4. Robertson DRC, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol. 1988;25:297-305.
5. Murdoch D, Heel RC. Amlodipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1991;41:478-505.
6. Todd A, Faulds D. Felodipine: a review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44:251-277.
7. Elliot HL, Meredith PA, Reid JL, et al. A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S64-S66.
8. Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22:21-25.
9. Leenen FHH, Coletta E, White R. Sympathoexcitatory responses to oncedaily dihydropyridines in young versus older hypertensives. Amlodipine versus felodipine-extended release. J Hypertens. 2006;24:177-184.
10. Beresford AP, Macrae PV, Stopher SA, et al. Analysis of amlodipine in humans plasma by gas chromatography. J Chromatogr B Biomed Appl. 1987;420:178-183.
11. Dru JD, Hsieh JY, Matuszewski BK, et al. Determination of felodipine in human plasma by capillary gas chromatography with mass spectrometric detection. J Chromatogr. 1995;666:259-267.
12. Bainbridge AD, Herlihy O, Meredith PA, et al. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol. 1993;45:425-430.
13. Blychert E, Edgar B, Elmfeldt D, et al. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol. 1991;31: 15-24.
14. Jiang GC, Iwanov V, Moulds RFW. The difference in nifedipine sensitivity between hypertensive and normotensive aortae is dependent on age. Clin Exp Pharmacol Physiol. 1995;22:17-20.
15. White M, Fourney A, Mikes E, et al. Effects of age and hypertension on cardiac responses to the α1-agonist phenylephrine in humans. Am J Hypertens. 1999;12:151-158.
16. Summer DJ, Meredith PA, Howie CA, et al. Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol. 1988;26:715-720.
17. Mason RP, Marche P, Hintze TH. Novel vascular biology of thirdgeneration L-type calcium channel antagonists-ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
18. Leenen FHH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after ''missed doses'' of calcium-antagonist with long (amlodipine) versus short (diltiazem) elimination half-life. Br J Clin Pharmacol. 1996;41:83-88.
19. Arrowsmith JE, Campbell SF, Cross PE, et al. Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem. 1986;29:1696-1702.
20. Rigby JW, Gardiner DG, Greengrass PM. Amlodipine: interaction with calcium channel binding sites. J Cardiovasc Pharmacol. 1988;12 (Suppl 6):S144.